WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V ... rights for Kane’s revyve TM Antimicrobial Wound Gel. BioStem made the announcement on November 20, 2024.
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE ... s revyveTM Antimicrobial Wound Gel. BioStem made the announcement on November 20, 2024. The company indicated ...
(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the ...
WINNIPEG, Manitoba, Nov. 27, 2024 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX- V:KNE ... exclusive US distribution rights for Kane's revyve TM Antimicrobial Wound Gel. BioStem made the announcement on ...
(the “Company” or “Kane Biotech”) announces today that it has received Health Canada approval of its revyve™ Antimicrobial Wound Gel as a Class 2 Medical Device. This approval allows the Company to ...
The company indicated that the acquisition of revyveTM Antimicrobial Wound Gel reflects BioStem's continued ... spectrum and around the world. Kane Biotech Inc. is a biotechnology company engaged ...
The biopharmaceutical sector showed signs of recovery in the third quarter of 2024, fueled by increased investor optimism following the U.S. Federal Reserve’s interest rate cuts in September.
(“Kane Biotech” or “Kane”) announces that it is donating 2,000 ounces of revyve™ Antimicrobial Wound Gel to the Ukraine medical relief effort. The product ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback